UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------|-------------------------------------------| | | | | For the transition | ______ | | Commission | 001-34810 | | A ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Nicole Sandford - CEO Sandy Milligan - President Torsten Hombeck - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Maggie Boeye - William Blair Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. Follo ...

Aspira (AWH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $10.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this diagnostic and bio-analytical company would post a loss of $0.39 per share when it actually produced a loss of $0.30, delivering a surprise of 23.08%.Over the last four quarters, the ...

Aspira Women's Health Reports First Quarter 2024 Financial Results Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, to ...

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for ...

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a new agreement with Anthem Blue Cross in California for reimbursement coverage of the Company's OvaSuiteSM portfolio of risk assessment tests effective June 1, 2024. Anthem Blue Cross will provide coverage for its commercial and government lines of business, inc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 ___________________________ FORM 10-K T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) Dela ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q4 2023 Results Conference Call March 28, 2024 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Sally Yanchus - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. Fourth Quarter and '23 Year-end Earnings Conference Call. [Operator Instructions] As a reminder, thi ...

Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company's product development team following the departure of Dr. Jody Berry AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on ...

Hi-Precision Laboratories, one of the largest medical laboratories in the Philippines, signs a 5-year OvaSuitSM commercial distribution agreement AUSTIN, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or "the Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the signing of a 5-year distribution agreement granting Hi-Precision Laboratories the exclusive right to market and di ...